Could a new drug quiet the ringing and dizziness of Meniere's disease?
NCT ID NCT02603081
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests an experimental drug called SPI-1005 (ebselen) in adults with Meniere's disease, a condition that causes vertigo, tinnitus, and hearing loss. The trial compares three doses of SPI-1005 against a placebo to see if it safely reduces these symptoms. Researchers will monitor side effects, drug levels in the blood, and changes in hearing and balance over several weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SPI-1005 (ebselen)
What this could lead to
If successful, SPI-1005 could offer a new treatment option to reduce vertigo attacks and hearing loss in people with Meniere's disease.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply to everyone. The drug's safety and effectiveness are still unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENIERE'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
House Clinic
Los Angeles, California, 90057, United States
-
MUSC
Charleston, South Carolina, 29425, United States
-
New York Otology
New York, New York, 10028, United States
-
Northwest Ear
Seattle, Washington, 98104, United States
-
Sound Pharmaceuticals, Inc.
Seattle, Washington, 98103, United States